Penpulimab
Showing 1 - 25 of 53
Pheochromocytoma, Metastatic, Pheochromocytoma Malignant, Paraganglioma, Malignant Trial in Beijing (Penpulimab)
Recruiting
- Pheochromocytoma, Metastatic
- +2 more
- Penpulimab
-
Beijing, ChinaPeking Union Medical College Hospital
May 31, 2023
Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma Trial in Beijing (Anlotinib Hydrochloride
Not yet recruiting
- Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
- Anlotinib Hydrochloride Capsule and Penpulimab
-
Beijing, Beijing, ChinaYansongLin
Sep 25, 2023
Pancreatic Adenocarcinoma Metastatic Trial in Nanjing (Penpulimab, Anlotinib, Nab paclitaxel)
Recruiting
- Pancreatic Adenocarcinoma Metastatic
- Penpulimab
- +3 more
-
Nanjing, Jiangsu, ChinaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University
Sep 18, 2023
Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Penpulimab injection, cisplatin, albumin-paclitaxel)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Penpulimab injection
- +2 more
-
Shanghai, Shanghai, ChinaShanghai Ninth People's Hostipal, Shanghai Jiao Tong University
Oct 7, 2023
Penpulimab in Maintenance Therapy in Lymphoma
Not yet recruiting
- Lymphoma
- Penpulimab
- (no location specified)
Dec 25, 2022
Advanced Cancer Trial in Chengdu, Hangzhou (TQB2223 injection+ Penpulimab Injection)
Recruiting
- Advanced Cancer
- TQB2223 injection+ Penpulimab Injection
-
Chengdu, Sichuan, China
- +1 more
Jun 7, 2023
Nasopharyngeal Tumors Trial (The combination treatment of anlotinib, penpulimab and capecitabine.)
Not yet recruiting
- Nasopharyngeal Neoplasms
- The combination treatment of anlotinib, penpulimab and capecitabine.
- (no location specified)
Apr 10, 2023
Breast Cancer Trial in Chengdu (Disitamab Vedotin, Penpulimab)
Not yet recruiting
- Breast Cancer
- Disitamab Vedotin
- Penpulimab
-
Chengdu, Chengdu, Sichuan, China, ChinaWest China Hospital, Sichuan University
Feb 9, 2023
Classic Hodgkin Lymphoma Trial (Concurrent penpulimab and AVD, Sequential penpulimab and AVD)
Not yet recruiting
- Classic Hodgkin Lymphoma
- Concurrent penpulimab and AVD
- Sequential penpulimab and AVD
- (no location specified)
Jul 10, 2023
Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma Trial in China (TQB2618 injection,
Not yet recruiting
- Recurrent Squamous Cell Carcinoma of the Head and Neck
- Metastatic Squamous Cell Carcinoma
- TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
- Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
-
Lanzhou, Gansu, China
- +11 more
Mar 23, 2023
Hepatocellular Carcinoma Trial (TACE+penpulimab+anlotinib vs. penpulimab+anlotinib)
Not yet recruiting
- Hepatocellular Carcinoma
- TACE+penpulimab+anlotinib vs. penpulimab+anlotinib
- (no location specified)
Apr 18, 2022
Esophageal Squamous Cell Carcinoma Trial in Shanghai (Penpulimab Combined With CRT)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Penpulimab Combined With CRT
-
Shanghai, Shanghai, ChinaZhongshan Hospital
Sep 28, 2022
Nasopharyngeal Carcinoma Trial in China (TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride
Recruiting
- Nasopharyngeal Carcinoma
- TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
- +2 more
-
Guangzhou, Guangdong, China
- +3 more
Nov 28, 2022
Rectal Cancer, Locally Advanced Trial (radiation, drug, procedure)
Not yet recruiting
- Rectal Cancer
- Locally Advanced
- Short-course radiotherapy
- +3 more
- (no location specified)
Oct 8, 2022
NSCLC Trial (Anlotinib Hydrochloride, penpulimab, SBRT)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Anlotinib Hydrochloride
- +2 more
- (no location specified)
Aug 2, 2022
Advanced Hepatocellular Carcinoma Trial in China (Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules)
Recruiting
- Advanced Hepatocellular Carcinoma
- Penpulimab injection
- +2 more
-
Wuwei, Gansu, China
- +7 more
Jul 27, 2023
Non Small Cell Lung Cancer Trial in Changsha (Anlotinib Plus Penpulimab)
Recruiting
- Non Small Cell Lung Cancer
- Anlotinib Plus Penpulimab
-
Changsha, Hunan, ChinaHunan Cancer hospital
Jul 17, 2022
NSCLC Trial (penpulimab combined with anlotinib)
Not yet recruiting
- NSCLC
- penpulimab combined with anlotinib
- (no location specified)
May 18, 2022
Pancreatic Tumors Trial in Nanjing (Penpulimab, Anlotinib, Nab paclitaxel)
Recruiting
- Pancreatic Neoplasms
- Penpulimab
- +3 more
-
Nanjing, Jiangsu, ChinaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University
Aug 10, 2022
Advanced Esophageal Squamous Cell Carcinoma Trial in China (TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin,
Not yet recruiting
- Advanced Esophageal Squamous Cell Carcinoma
- TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin
- +2 more
-
Tongling, Anhui, China
- +9 more
Apr 18, 2023
Carcinoma, Gastrointestinal Diseases, Stomach Cancer Trial (Anlotinib HCl capsule, Penpulimab Injection, XELOX)
Not yet recruiting
- Carcinoma
- +6 more
- Anlotinib hydrochloride capsule
- +2 more
- (no location specified)
Aug 8, 2022
Essential Tremor Trial (Anlotinib/Penpulimab/Chemotherapy, Penpulimab/Chemotherapy)
Not yet recruiting
- Essential Tremor
- (no location specified)
Jan 14, 2022
Bladder Cancer Trial (Disitamab Vedotin for Injection,Penpulimab Injection)
Not yet recruiting
- Bladder Cancer
- Disitamab Vedotin for Injection,Penpulimab Injection
- (no location specified)
Aug 2, 2022
Primary CNS Lymphoma Trial (Penpulimab)
Not yet recruiting
- Primary Central Nervous System Lymphoma
- Penpulimab
- (no location specified)
Apr 20, 2022
Esophageal Squamous Cell Carcinoma Trial (Decitabine plus Penpulimab)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Decitabine plus Penpulimab
- (no location specified)
Feb 23, 2022